Search bioRxiv⌕ Search

bioRxiv · 10.1101/2022.11.09.515776

A novel deep learning pipeline for cell typing and phenotypic marker quantification in multiplex imaging

Abstract

BackgroundMultiplex immunofluorescence (mIF) can provide invaluable insights into spatial biology and the complexities of the immune tumor microenvironment (iTME). However, existing analysis approaches are both laborious and highly user-dependent. In order to overcome these limitations we developed a novel, end-to-end deep learning (DL) pipeline for rapid and accurate analysis of both tumor-microarray (TMA) and whole slide mIF images. MethodsOur pipeline consists of two DL models: a multi-classifier for classifying multi-channel cell images into 12 different cell types, and a binary classifier for determining the positivity of a given marker in single-channel images. The DL multi-classifier was trained on 7,000 tiles labeled with cell annotations from a publicly available CODEX dataset, consisting of 140 tissue cores from 35 colorectal cancer (CRC) patients. For the binary classifier training, the multi-channel tiles were further split into [~]100,000 single-channel tiles, for which the ground truth was inferred from the known expression of these markers in each cell-type. This DL binary classifier was then utilized to quantify the positivity of various cell state (phenotypic) markers. In addition, the binary classifier was exploited as a cell-typing tool, by predicting the positivity of individual lineage cell markers. The performance of our DL models was evaluated on 1,800 annotations from 14 test tissue cores. The models were further evaluated on a new 6-plex melanoma cohort, stained with PhenoImager(R), and were compared to the performance of clustering, manual thresholding or machine learning-based cell-typing methods applied on the same test sets. ResultsOur DL multi-classifier achieved highly accurate results, outperforming all of the tested cell-typing methods, including clustering, manual-thresholding and ML-based approaches, in both CODEX CRC and PhenoImager melanoma cohorts (accuracy of 91% and 87%, respectively), with F1-scores above 80% in the vast majority of cell types. Our DL binary classifier, which was trained solely on the lineage markers of the CRC dataset, also outperformed existing methods, demonstrating excellent F1-scores (>80%) for determining the positivity of unseen phenotypic and lineage markers across the two tumor types and imaging modalities. Notably, as little as 20 annotations were required in order to boost the performance on an unseen dataset to above 85% accuracy and 80% F1-scores. As a result, the DL binary classifier could successfully be used as a cell-typing model, in a manner that is transferable between experimental approaches. ConclusionsWe present a novel state-of-the-art DL-based framework for multiplex imaging analysis, that enables accurate cell typing and phenotypic marker quantification, which is robust across markers, tumor indications, and imaging modalities.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Markovits, E., Dankovich, T., Gluskin, R., Weiss, I., Gutwillig, A., Dicker, T., Dagan, S., Elran, R., Arbiv, B., Shachaf, Y., Bart, A., Debby, A., Asher, N., Ben-Betzalel, G., Shapira-Frommer, R., Barshack, I., Zelichov, O.. 2022-11-10. A novel deep learning pipeline for cell typing and phenotypic marker quantification in multiplex imaging. https://doi.org/10.1101/2022.11.09.515776

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

De novo design of CR2 binder as vaccine scaffold

Efficient B cell activation during vaccine-induced humoral immunity relies on both B cell receptor (BCR) antigen recognition and synergistic signaling from co-receptors. Complement receptor 2 (CR2), the primary BCR co-receptor on B cells, lowers the activation threshold and amplifies downstream kinase signaling by orders of magnitude when engaged by complement fragment C3d decorated antigens. Targeting CR2 therefore represents a rational vaccine enhancement strategy, yet native C3d suffers from low affinity, poor stability, and manufacturing challenges. Here, we report the de novo design of a highly stable, high-affinity CR2 binder using deep learning driving protein design methods. Biophysical characterization, high-resolution cryoEM structural determination, and functional assays in vitro and in vivo confirm that the designed binder matches computational design models and specifically engages CR2 to boost B cell activation. When fused to antigen as a vaccine scaffold, the trimeric CR2 binder elicits robust humoral immune responses comparable to nanoparticle vaccines, while retaining the simplicity of single-chain protein production. Our work establishes a modular CR2 targeting vaccine scaffold platform with broad translational potential for next-generation protein vaccines.

immunology↗

Chronic opioid-associated immune dysregulation among people living with HIV

Objectives: Persistent immune dysregulation contributes to chronic disease among people living with HIV (PWH), even after viral suppression with antiretroviral therapy (ART). Although chronic opioid exposure is associated with adverse clinical outcomes, its impact on immune homeostasis during ART remains incompletely understood. We investigated whether opioid use disorder (OUD) is associated with persistent systemic and cellular immune dysregulation despite ART-mediated reductions in HIV viral load (VL). Methods: Peripheral blood was collected longitudinally from PWH with OUD (PWH/OUD+) and detectable HIV VL during 6 months of optimized ART (months 0, 3, and 6). A reference cohort of PWH without OUD (PWH/OUD-) and suppressed HIV VL provided a single blood sample. Immune profiling included plasma inflammatory biomarkers, multiplex cytokine analyses, spectral flow cytometry, and assessment of monocyte cytokine responses following lipopolysaccharide (LPS) stimulation. Mixed-effects models adjusted for HIV VL and VL-stratified analyses were performed. Results: PWH/OUD+ exhibited persistent immune dysregulation despite reductions in HIV VL. Plasma sCD163, sCD14, fractalkine, and I-TAC remained elevated, whereas TGF-{beta}1 was reduced. OUD was associated with expansion of CD16 monocytes and altered expression of CCR2, CD38, and CD11b. CD4 and CD8 T cells, NK cells, and B cells also exhibited persistent alterations in markers of activation, metabolism, and trafficking. Monocytes from PWH/OUD+ displayed attenuated cytokine responses following LPS stimulation. Conclusions: OUD is associated with persistent systemic and cellular immune dysfunction in PWH despite ART-mediated viral suppression, supporting opioid exposure as an independent contributor to chronic immune dysregulation that may promote inflammation, immune dysfunction, and long-term HIV-associated comorbidities. Keywords: HIV, Opioid-use disorder, innate immunity, cytokine

immunology↗

The mitochondrial RNA extrusion-induced innate immunity is regulated by N6-methyladenosine machinery

Mitochondrial RNA (mtRNA) released into the cytosol functions as a damage associated molecular pattern that activates pattern-recognition receptor (PRR)-mediated inflammation, yet its release mechanisms and cytoplasmic fate remain poorly understood. Here we report that chemical Abt-373-treatment and Vesicular stomatitis virus (VSV) infection induce mtRNA extrusion through Bax/Bak and VDAC1 channels, accompanied by mtDNA release. Extruded mtRNA in A549 cells activates multiple cytosolic PRRs, including RIG-I, MDA5, TLR3/7/8, and PKR, each contributing differentially to the innate immune signaling. Analysis of GEO datasets and methylated RNA immunoprecipitation (MeRIP) assays further reveals that mtRNA carries methyladenosine (m6A) modification. m6A machinery proteins are involved in the cytoplasmic retention time of mtRNA and its interaction with RIG-I, thereby modulating mtRNA-induced innate immunity. Thus, our work establishes in vitro models of mtRNA extrusion, and highlights m6A-dependent modulation as a potential therapeutic target for mtRNA-driven inflammation.

immunology↗